Dec 21, 2025 04:00AM
Dec 20, 2020 07:00PM
Dec 7, 2020 01:32PM
Dec 7, 2020 01:30PM
Nov 20, 2020 10:30AM
Nov 20, 2020 10:30AM
Nov 13, 2020 06:12AM Karyopharm Therapeutics (KPTI) Reports Publication of XPOVIO (Selinexor) Phase 3 BOSTON Study Results in The Lancet
Nov 12, 2020 07:06PM
Nov 2, 2020 05:03PM
Nov 2, 2020 04:05PM
Nov 2, 2020 04:03PM
Nov 2, 2020 04:01PM
Aug 4, 2020 07:00AM
Jun 12, 2020 07:03AM UPDATE: Karyopharm Therapeutics (KPTI) Announces XPOVIO (selinexor) and Eltanexor Data at EHA25 2020 Virtual Meetings
Jun 12, 2020 07:00AM
Jun 9, 2020 09:03AM
Jun 9, 2020 09:00AM
May 28, 2020 04:26PM
May 28, 2020 04:05PM
May 26, 2020 07:00AM
May 20, 2020 08:07AM Karyopharm Therapeutics (KPTI) Submits sNDA to FDA for XPOVIO as Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
May 20, 2020 08:00AM
May 5, 2020 08:30AM
May 5, 2020 07:00AM
Apr 29, 2020 01:58PM
Apr 20, 2020 07:06AM
Apr 20, 2020 07:00AM
Apr 7, 2020 07:04AM Karyopharm Therapeutics (KPTI) to Evaluate Low Dose Selinexor as Potential Treatment for Hospitalized Patients with COVID-19
Apr 7, 2020 07:00AM
Feb 19, 2020 08:10AM
Feb 19, 2020 08:00AM
Jul 3, 2019 10:53AM
May 9, 2019 07:02AM
May 9, 2019 07:02AM
Mar 15, 2019 09:25AM Pre-Open Stock Movers 03/15: (MDCA) (KPTI) (AVGO) Higher; (ASNA) (KOPN) (HEAR) Lower (more...)
Mar 15, 2019 09:05AM
Mar 14, 2019 04:59PM
Mar 14, 2019 04:57PM
Feb 28, 2019 07:00AM
Feb 28, 2019 07:00AM
Feb 27, 2019 06:37AM
Feb 27, 2019 06:24AM Karyopharm (KPTI) Confirms Panel Recommended FDA Wait for Results from Phase 3 BOSTON Study of Selinexor in Patients R/R MM before Making Final Decision on Approval
Feb 26, 2019 05:47PM
Feb 26, 2019 05:47PM
Feb 26, 2019 12:33PM
Feb 26, 2019 12:31PM
Feb 26, 2019 12:31PM
Feb 7, 2019 07:48AM
Feb 7, 2019 07:00AM Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies
Feb 7, 2019 07:00AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All